Your browser doesn't support javascript.
loading
Technical considerations for isolated limb perfusion: A consensus paper.
Hayes, Andrew J; Coker, David J; Been, Lukas; Boecxstaens, Veerle Wsm; Bonvalot, Sylvie; De Cian, Franco; de la Cruz-Merino, Luis; Duarte, Carlos; Eggermont, Alexander; Farricha, Victor; Fiore, Marco; Grünhagen, Dirk; Grützmann, Robert; Honoré, Charles; Jakob, Jens; Hocevar, Marko; van Houdt, Winan; Klauzner, Joseph; Kettelhack, Christoph; Märten, Angela; Martinez-Said, Hector; Matter, Maurice; Michot, Audrey; Niethard, Maya; Pennacchioli, Elisabetta; Podleska, Lars E; Rabago, Gregorio; Rastrelli, Marco; Reijers, Sophie; Ribeiro, Matilde; Schwarzbach, Matthias; Snow, Hayden A; Spacek, Miroslav; Stoldt, Stephan; Testori, Alessandro; Zoras, Odysseas; Olofsson Bagge, Roger.
Afiliação
  • Hayes AJ; Department of Academic Surgery, Royal Marsden Hospital, London, UK; Institute of Cancer Research, London, UK. Electronic address: Andrew.Hayes@rmh.nhs.uk.
  • Coker DJ; Department of Academic Surgery, Royal Marsden Hospital, London, UK; Department of Surgery, Royal Prince Alfred Hospital, Sydney, Australia; The University of Sydney, Sydney, Australia. Electronic address: drdavidjcoker@gmail.com.
  • Been L; Department of Surgical Oncology University Medical Center Groningen, University of Groningen, the Netherlands.
  • Boecxstaens VW; Department of Surgical Oncology, University Hospitals Leuven, Belgium.
  • Bonvalot S; Department of Surgery, Institute Curie, Paris, France.
  • De Cian F; Policlinico San Martino, University of Genoa, Genoa, Italy Clinical Oncology Department; Italy Clinical Oncology Department, Italy.
  • de la Cruz-Merino L; University Hospital Virgen Macarena, Seville, Spain.
  • Duarte C; Department of Surgical Oncology, Instituto Nacional de Cancerología, Bogota, Colombia.
  • Eggermont A; University Medical Center Utrecht and Princess Maxima Center, Utrecht, the Netherlands; Comprehensive Cancer Center München, Technical University München & Ludwig Maximilian University, Munich, Germany.
  • Farricha V; Melanoma and Sarcoma Unit, Department of Surgery, Portuguese Institute of Oncology, Lisbon, Portugal.
  • Fiore M; Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Grünhagen D; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC, Rotterdam, the Netherlands.
  • Grützmann R; Department of General and Visceral Surgery, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Honoré C; Sarcoma Unit, Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114, Rue Edouard Vaillant, Villejuif, France.
  • Jakob J; Sarcoma Unit, Interdisciplinary Tumor Center, Mannheim University Medical Center University of Heidelberg, Mannheim, Germany.
  • Hocevar M; Institute of Oncology Ljubljana, Slovenia.
  • van Houdt W; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, the Netherlands.
  • Klauzner J; Surgical Oncology- Melanoma, Division of Surgery, Sourasky Tel Aviv Medical Center (Ichilov Hospital), Tel Aviv University, Israel.
  • Kettelhack C; Clarunis, University Center for Gastrointestinal and Liver Disease Basel, Basel, Switzerland.
  • Märten A; Belpharma s.a., Luxembourg, Luxembourg.
  • Martinez-Said H; Deputy Direction of Surgical Oncology, Instituto Nacional de Cancerología, Mexico.
  • Matter M; Institut Bergonié Sarcoma Unit, '229 cours de l'Argonne, 33000, Bordeaux, France.
  • Michot A; Lausanne University Hospital and University of Lausanne Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, 1011, Lausanne CHUV, Switzerland.
  • Niethard M; Department of Orthopedic Oncology, Helios Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin, Germany.
  • Pennacchioli E; IRCSS Istituto Europeo di Oncologia, Milan, Italy.
  • Podleska LE; Department of Orthopaedic Oncology and Soft Tissue Sarcoma, Essen University Hospital, Hufelandstraße 55, 45147 Essen, Germany.
  • Rabago G; Department of Cardiovascular Surgery Clinica University of Navarra, Pamplona, Spain.
  • Rastrelli M; Department of Surgery, Oncology and Gastroenterology-DISCOG, University of Padua, Padua, Italy; Department of Surgery, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Reijers S; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, the Netherlands.
  • Ribeiro M; Instituto Português De Oncologia De Porto, 4200 Porto, Portugal.
  • Schwarzbach M; Varisano Klinikum Frankfurt Höchst, Frankfurt, Germany.
  • Snow HA; Peter MacCallum Cancer Centre, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
  • Spacek M; Second Department of Surgery-Department of Cardiovascular Surgery, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Stoldt S; Department of Abdominal and Paediatric Surgery, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
  • Testori A; Chairman surgical subgroup EORTC Melanoma Group, Brussels, Belgium; Direttore divisione dermatologia Oncologica, Image Institute, Milan, Italy.
  • Zoras O; Emeritus Professor of Surgical Oncology, University of Crete, Greece.
  • Olofsson Bagge R; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Eur J Surg Oncol ; 50(6): 108050, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38498966
ABSTRACT

BACKGROUND:

Isolated limb perfusion (ILP) is a well-established surgical procedure for the administration of high dose chemotherapy to a limb for the treatment of advanced extremity malignancy. Although the technique of ILP was first described over 60 years ago, ILP is utilised in relatively few specialist centres, co-located with tertiary or quaternary cancer centres. The combination of high dose cytotoxic chemotherapy and the cytokine tumour necrosis factor alpha (TNFα), mandates leakage monitoring to prevent potentially serious systemic toxicity. Since the procedure is performed at relatively few specialist centres, an ILP working group was formed with the aim of producing technical consensus guidelines for the procedure to streamline practice and to provide guidance for new centres commencing the technique.

METHODS:

Between October 2021 and October 2023 a series of face to face online and hybrid meetings were held in which a modified Delphi process was used to develop a unified consensus document. After each meeting the document was modified and recirculated and then rediscussed at subsequent meeting until a greater than 90% consensus was achieved in all recommendations.

RESULTS:

The completed consensus document comprised 23 topics in which greater than 90% consensus was achieved, with 83% of recommendations having 100% consensus across all members of the working group. The consensus recommendations covered all areas of the surgical procedure including pre-operative assessment, drug dosing and administration, perfusion parameters, hyperthermia, leakage monitoring and theatre logistics, practical surgical strategies and also post-operative care, response evaluation and staff training.

CONCLUSION:

We present the first joint expert-based consensus statement with respect to the technical aspects of ILP that can serve as a reference point for both existing and new centres in providing ILP.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quimioterapia do Câncer por Perfusão Regional / Extremidades Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quimioterapia do Câncer por Perfusão Regional / Extremidades Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article